In vivo expression of full-length human dystrophin from adenoviral vectors deleted of all viral genes.
Adenoviral vectors have been shown to effect efficient somatic gene transfer in skeletal muscle and thus offer potential for the development of therapy for Duchenne muscular dystrophy (DMD). Efficient transfer of recombinant genes has been demonstrated in skeletal muscle using recombinant adenoviruses deleted of E1. Application of this vector system to the treatment of DMD is limited by the vector immunogenicity, as well as by size constraints for insertion of recombinant genes, precluding the incorporation of a full-length dystrophin minigene construct. We describe in this study the use of helper adenovirus to generate a recombinant vector deleted of all viral open reading frames and containing a full-length dystrophin minigene. We show that this deleted vector (delta vector) is capable of efficiently transducing dystrophin in mdx mice, in myotubes in vitro and muscle fibers in vivo. Our modification of adenoviral vector technology may be useful for the development of gene therapies for DMD and other diseases.
Institute for Human Gene Therapy, University of Pennsylvania, Philadelphia, 19104, USA.
S E
SE
Haecker
H H
HH
Stedman
R J
RJ
Balice-Gordon
D B
DB
Smith
J P
JP
Greelish
M A
MA
Mitchell
A
A
Wells
H L
HL
Sweeney
J M
JM
Wilson
D000256:Adenoviridae / Q000235:genetics*; D000818:Animals; D018076:DNA, Complementary / Q000737:chemistry; D016189:Dystrophin / Q000235:genetics*; D005814:Genes, Viral; D015316:Genetic Therapy / Q000379:methods; D005822:Genetic Vectors; D006801:Humans; D051379:Mice; D008810:Mice, Inbred C57BL; D018482:Muscle, Skeletal / Q000378:metabolism; D009693:Nucleic Acid Hybridization; D011994:Recombinant Proteins / Q000235:genetics / Q000378:metabolism; D014161:Transduction, Genetic
D018076:DNA, Complementary; D016189:Dystrophin; D011994:Recombinant Proteins